Aegerion Pharmaceuticals (NASDAQ: AEGR) is up 30%, thanks to a presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference. Analysts have literally rushed out and threw upgrades at the stock after the company announced a price hike for HoFH drug Juxtapid.

In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion, and also for its competitors.